David Friedman

Dr. Friedman is a Managing Director and Senior Analyst for the Averill Strategy at Suvretta Capital Management, LLC. Prior to joining Suvretta Capital, Dr. Friedman was a Healthcare Analyst at Scopia Capital Management where he focused on biotechnology/specialty pharmaceutical companies and led the healthcare capital markets efforts. Prior to Scopia, Dr. Friedman worked in biotechnology equity research at Morgan Stanley. Dr. Friedman earned a Bachelor of Science degree in Biology from Duke University, received an MD from the University of Pittsburgh School of Medicine, performed general surgery residency training at the Massachusetts General Hospital, and obtained an MBA from Harvard Business School.